Daclizumab 
Brand name:- Zenapax .
Daclizumab works by blocking the function of T-cell, a type of white blood which prevent the body’s immune system from damaging your brain and spinal cord. This helps to reduce the disability due to these disorders.
Pharmacodynamic:-
Zenapax functions as an IL-2 receptor antagonist. Specifically it inhibits IL-2-mediated activation of lymphocytes, a critical pathway in the cellular immune response involved in allograft rejection.
Pharmacokinetics:-
After subcutaneous injection of a single dose, daclizumab has a bioavailability of about 90% and reaches highest blood plasma levels after 5 to 7 days. Given every four weeks, steady state concentrations are found after the fourth dose. It is expected that daclizumab, like other antibodies, is degraded by proteases to peptides and finally amino acids, and that it does not interact with cytochrome P450 liver enzymes.
The biological half-life is 21 days. Patients who developed antibodies against daclizumab eliminated it 19% faster.
Mechanism of action:-
Daclizumab blocks IL-2 receptors containing the alpha subunit (CD25), which include the high-affinity receptors. Medium-affinity receptors, on the other hand, consist of two beta subunits (CD122) and are not affected by daclizumab. While the exact mechanism is unknown, the net effect is a reduction of T-cell responses and expansion of CD56bright natural killer cells.
Used:-
Used to treat the relapsing forms of multiple sclerosis (MS). This medicine will not cure MS, but it may slow some of the disabling effects and decrease the number of relapses of the disease. It should only be used when other medicines to treat MS did not work well.
Side effects:-
Upper respiratory tract infection.
Comments
Post a Comment